Latest news with #Keytruda
South Wales Guardian
2 hours ago
- Health
- South Wales Guardian
Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care. It also slashed the risk of the disease returning in another part of the body, the study suggests. Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box. Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers. The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients. Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only. Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer. By blocking this protein, the treatment helps the immune system fight cancer more effectively. The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body. The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care. After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades. 'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas. 'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.' Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'. 'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said. It is estimated there are about 12,800 cases of head and neck cancer in the UK each year.
Scotsman
4 hours ago
- Health
- Scotsman
Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial has found. Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial has found. Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care. Advertisement Hide Ad Advertisement Hide Ad It also slashed the risk of the disease returning in another part of the body, the study suggests. Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box. Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers. The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients. Advertisement Hide Ad Advertisement Hide Ad Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only. Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer. By blocking this protein, the treatment helps the immune system fight cancer more effectively. The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body. Advertisement Hide Ad Advertisement Hide Ad The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care. After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades. 'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas. Advertisement Hide Ad Advertisement Hide Ad 'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.' Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'. 'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said.
Belfast Telegraph
5 hours ago
- Health
- Belfast Telegraph
Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care. It also slashed the risk of the disease returning in another part of the body, the study suggests. Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box. Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers. The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients. Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only. Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer. By blocking this protein, the treatment helps the immune system fight cancer more effectively. The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body. The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care. After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades. 'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas. 'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.' Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'. 'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said. It is estimated there are about 12,800 cases of head and neck cancer in the UK each year.
North Wales Chronicle
8 hours ago
- Health
- North Wales Chronicle
Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care. It also slashed the risk of the disease returning in another part of the body, the study suggests. Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box. Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers. The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients. Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only. Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer. By blocking this protein, the treatment helps the immune system fight cancer more effectively. The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body. The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care. After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades. 'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas. 'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.' Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'. 'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said. It is estimated there are about 12,800 cases of head and neck cancer in the UK each year.
Powys County Times
8 hours ago
- Health
- Powys County Times
Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial has found. Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care. It also slashed the risk of the disease returning in another part of the body, the study suggests. Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box. Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers. The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients. Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only. Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer. By blocking this protein, the treatment helps the immune system fight cancer more effectively. The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body. The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care. After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades. 'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas. 'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.' Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'. 'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said.
